Cytokines and growth factors cross-link heparan sulfate

Elisa Migliorini1,2,3, Dhruv Thakar1,2, Jens Kühne4, Rabia Sadir5,6,7, Douglas P. Dyer3, Yong Li9, Changye Sun5, Brian F. Volkman10, Tracy M. Handel11, Liliane Coche-Guerente1,2, David G. Fernig9, Hugues Lortat-Jacob5,6,7 and Ralf P. Richter1,2,3,11

1 Université Grenoble Alpes, Département de Chimie Moléculaire (DCM), Grenoble, France
2 CNRS, DCM, Grenoble, France
3 CIC biomaGUNE, San Sebastian, Spain
4 Department of Biophysical Chemistry, University of Heidelberg, Heidelberg, Germany
5 Université Grenoble Alpes, Institut de Biologie Structurale (IBS), Grenoble, France
6 CNRS, and CEA, IBS, Grenoble, France
7 University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA
8 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK
9 Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA
10 Max Planck Institute for Intelligent Systems, Stuttgart, Germany

The glycosaminoglycan heparan sulfate (HS), present at the surface of most cells and ubiquitous in extracellular matrix, binds many soluble extracellular signalling molecules such as chemokines and growth factors, and regulates their transport and effector functions. It is, however, unknown whether upon binding HS these proteins can affect the long-range structure of HS. To test this idea, we interrogated a supramolecular model system, in which HS chains grafted to streptavidin-functionalized oligoethylene glycol monolayers or supported lipid bilayers mimic the HS-rich pericellular or extracellular matrix, with the biophysical techniques quartz crystal microbalance (QCM-D) and fluorescence recovery after photobleaching (FRAP). We were able to control and characterize the supramolecular presentation of HS chains—their local density, orientation, conformation and lateral mobility—and their interaction with proteins. The chemokine CXCL12α (or SDF-1α) rigidified the HS film, and this effect was due to protein-mediated cross-linking of HS chains. Complementary measurements with CXCL12α mutants and the CXCL12γ isoform provided insight into the molecular mechanism underlying cross-linking. Fibroblast growth factor 2 (FGF-2), which has three HS binding sites, was also found to cross-link HS, but FGF-9, which has just one binding site, did not. Based on these data, we propose that the ability to cross-link HS is a generic feature of many cytokines and growth factors, which depends on the architecture of their HS binding sites. The ability to change matrix organization and physico-chemical properties (e.g. permeability and rigidification) implies that the functions of cytokines and growth factors may not simply be confined to the activation of cognate cellular receptors.

1. Background

Heparan sulfate (HS) is a linear polysaccharide made of variably sulfated repeating disaccharide units. Attached to extracellular matrix or cell-surface proteins (HS proteoglycans, HSPGs), it pervades the intercellular space of many tissues and the periphery of virtually all mammalian cells. HS binds many soluble extracellular signalling molecules such as growth factors and chemokines, and these interactions are known to be important for various physiological and pathological processes [1–4] including organogenesis and growth control [5,6], cell adhesion.
[7] and signalling [8], inflammation [9], tumour development [10] and interactions with pathogens [11].

Past studies have revealed how HS–protein interactions determine protein function. For example, HS (as well as the highly sulfated analog heparin) plays a role in the specificity and control of the engagement of fibroblast growth factors (FGFs) with their cell-surface receptors, through the formation of stable ternary complexes [12], thus modulating cell signalling. The binding of chemokines to HS in the extracellular space, on the other hand, enables the formation of chemokine gradients [13], thus providing directional cues and guiding the migration of appropriate cells in the context of their inflammatory, developmental and homeostatic functions.

By contrast, very little is known about the effect of signalling proteins on HS and HSPGs. HS chains are typically a few tens of nanometres in length [14] and, thus, possess multiple binding sites enabling simultaneous binding of several proteins [15]. These interactions will influence the molecular structure of individual HS chains. Moreover, they may also profoundly affect the supramolecular organization of HS in the extracellular space. Such long-range effects have hitherto been difficult to test, because of the lack of appropriate structural and biochemical methods.

Here, we demonstrate that several soluble extracellular signalling proteins can effectively cross-link HS. To this end, we developed an in vitro binding assay that is based on films of surface-grafted HS chains, as a well-defined model of HS-rich pericellular or extracellular matrix [7], and a combination of two biophysical analysis techniques: quartz crystal microbalance (QCM-D) and fluorescence recovery after photobleaching (FRAP). These techniques provide insight into the binding of proteins to the HS film, and the concomitant changes in film morphology and HS chain mobility. Through the analysis of a set of proteins and their mutants—including chemokines, cytokines and growth factors—with this assay, we identify molecular features that determine the HS cross-linking propensity of extracellular signalling proteins. The ability to cross-link, and thus to change matrix organization and physico-chemical properties, implies that the functions of these proteins may not simply be confined to the activation of cognate cellular receptors, and we discuss possible physiological implications.

2. Material and methods

2.1. Buffer

The working buffer used for all measurements contained 10 mM HEPES (Fisher, Illkirch, France) at pH 7.4 and 150 mM NaCl (Sigma-Aldrich, Saint-Quentin Fallavier, France).

2.2. Heparan sulfate and proteins

The HS polysaccharide derived from porcine intestinal mucosa (Celsius Laboratories, Cincinnati, OH, USA) was found to have an average molecular weight of 12 kDa and a polydispersity of 1.6 [16]. Size-uniform HS oligosaccharides from hexasaccharide (degree of polymerization, dp6) to dodecasaccharide (dp12) were derived from this source, as previously described [17]. HS was conjugated with biotin through an oligoethylene glycol (OEG) linker of approximately 1 nm length, site-specifically attached to the reducing end by oxime ligation. In contrast to the conventionally used hydrazide ligation, oxime ligation produces conjugates that are stable for many weeks in aqueous solution [18]. HS conjugates were stored at a concentration of 10 mg ml⁻¹ at -20 °C until further use.

Recombinant CXCL12α (amino acids 1 to 68; 8.1 kDa) was prepared as previously described [19]. A truncated CXCL12α construct (amino acids 5 to 67; 7.4 kDa [20]) was produced by solid-phase peptide synthesis, as previously reported [4,15]. An I55C/L58C mutant of CXCL12α with reduced dimerization propensity (‘partial monomer’) was prepared as previously described [21]. An L36C/A65C mutant of CXCL12α in which the introduced cysteines promote the formation of dimers (‘locked dimer’) was prepared, as described in Veldkamp et al. [22]. The cDNA of murine CXCL12γ was inserted in a pET-17b vector (Novagen, Merck Chemical Ltd., Nottingham, UK) between NdeI and SpeI restriction sites, checked by DNA sequencing, and the protein (11.6 kDa) was produced by recombinant expression in Escherichia coli strain BL21 Star DE3, as previously reported [23]. Interferon (IFN)γ (17 kDa) was produced by recombinant expression in E. coli strain BL21 Star DE3 using a pET-11a vector (Novagen), as previously reported [24]. Recombinant FGF-2 (18 kDa) and FGF-9 (26 kDa) were obtained by expression in C41 E. coli cells using pET-14b and pET-M11 for vectors (Novagen), respectively, as described by Xu et al. [25].

Lyophilized streptavidin (SAv), fluorescently labelled SAv (fl-SAv; with atto565) and bovine serum albumin (BSA) were obtained from Sigma-Aldrich. All proteins were stored in working buffer at -20 °C until further use. Thawed protein solutions were used within 5 days.

2.3. Surfaces and surface functionalization with a biotin-displaying and otherwise inert background

QCM-D sensors with gold (QSX301) and silica (QSX303) coatings (Biolin Scientific, Västra Frölunda, Sweden) were used as is. Glass coverslips (24 × 24 mm²; Menzel-Gläser, Braunschweig, Germany) for FRAP assays were cleaned by immersion in freshly prepared piranha solution (i.e. a 1 : 3 (v/v) mixture of H₂O₂ (Fisher Scientific) and concentrated H₂SO₄ (Sigma-Aldrich)) for 1 h, rinsing with ultrapure water and blow-drying with N₂. All substrates were exposed to UV/ozone (Jetlight Company, CA, USA) for 10 min prior to use.

Gold surfaces were functionalized with biotin-displaying monolayers of OEG as previously described [7]. Briefly, the gold-coated surfaces were immersed overnight in an ethanolic solution of OEG disulfide and biotinylated OEG thiol (Polypure, Oslo, Norway), at a total concentration of 1 mM and a molar ratio of thiol equivalents of 999 : 1. Silica (for QCM-D) and glass (for FRAP) surfaces were functionalized with biotin-displaying supported lipid bilayers (SLBs) by the method of vesicle spreading, as described in detail elsewhere [26]. Briefly, the surfaces were exposed for 30 min to small unilamellar vesicles, made from a mixture of dioleoylphosphatidylcholine (DOPC) and dioleoylphosphatidylethanolamine-CAP-biotin (DOPC-CAP-b) (Avanti Polar Lipids, Alabaster, AL, USA) at the desired molar ratio (99.5 : 0.5 or 95 : 5) at a total concentration of 50 μg ml⁻¹ in working buffer supplemented with 2 mM CaCl₂ (VWR International, Leuven, Belgium).
2.4. Assembly of HS films

Biotin-displaying surfaces were further functionalized for studies of protein interactions with well-defined HS films, as described in detail earlier [7]. Briefly, the surfaces were first exposed to SAv, to form a SAv-monolayer, and then to biotinylated HS (b-HS), to form a molecular film of HS that is site-specifically attached through the reducing end to the surface. This mode of attachment avoids any perturbation of protein–HS interactions through chemical modifications along the HS chain [27, 28]. Sample concentrations and incubation times were chosen such that binding either saturates or equilibrates, unless otherwise stated.

2.5. Quartz crystal microbalance with dissipation monitoring

Quartz crystal microbalance with dissipation monitoring (QCM-D) measurements were performed, as previously described [7]. QCM-D measures changes in frequency,Δf, and in dissipation, ΔD, of a quartz sensor upon interaction of molecules with its surface. Measurements were performed with a Q-Sense E4 system equipped with Flow Modules (Biolin Scientific) with a flow rate of typically 10 μl min⁻¹ and at a working temperature of 24°C. QCM-D data were collected at six overtones (n = 3, 5, 7, 9, 11, 13, corresponding to resonance frequencies of approximately 15, 25, 35, 45, 55, 65 MHz). For the sake of simplicity, only changes in dissipation and normalized frequency, Δf = Δfₙ/ν, of the third overtone (n = 3) are presented. Any other overtone would have provided comparable information.

A viscoelastic model [29], implemented in the software QTM (Diethelm Johannsman, Clausthal University of Technology; http://www2.pc.tu-clausthal.de/dij/software_en.shtml), was used to quantify the thickness d and viscoelastic properties of HS films from QCM-D data. Details of the fitting procedure are described elsewhere [30]. We parameterized viscoelastic properties in terms of the elastic and viscous compliances J′ and J″ at a reference frequency of f = 15 MHz (i.e. close to the resonance frequency at n = 3). J′ and J″ are measures for the softness of the film. The elastic compliance can also be estimated directly from the QCM-D responses for the film through the approximate relationship ∆D/(−∆f) = 4πηµ/ρ × f, where η = 0.89 mPa·s and ρ = 1.0 g cm⁻³ are the viscosity and density of the aqueous bulk solution, respectively, and ρ ≈ 1.0 g cm⁻³ is the film density [31].

2.6. Fluorescence recovery after photobleaching

For fluorescence recovery after photobleaching (FRAP) assays, cleaned glass coverslips were attached, using a bi-component glue (Picodent, Wipperfürth, Germany), to a custom-built teflon holder, thus forming the bottom of four identical wells with a volume of 50 μl each. All surface functionalization steps were performed in still solution. To remove excess sample after each incubation step, the content was diluted by repeated addition of a twofold excess of working buffer and removal of excess liquid until the concentration of the solubilized sample, estimated from the extent of dilution, was below 10 ng ml⁻¹. Repeated aspiration and release ensured homogenization of the liquid volume at each dilution step. Care was taken to keep the substrates wet at all times.

FRAP measurements were performed with a confocal laser scanning microscope (LSM 700, Zeiss, Germany) using a laser with 555 nm wavelength, a plan-apochromat 63×/1.4 oil immersion objective and a fully opened pinhole (1 mm diameter). fl-SAv, attached to biotin-displaying SLBs, was used as a fluorophore to report on the lateral mobility of SAv-bound HS. After acquiring three pre-bleach images, a circular region with a radius of 10 μm in the centre of the imaged area was bleached through exposure for approximately 20 s to high laser intensity; approximately 80% bleaching in the centre of the exposed area was achieved. The fluorescence recovery due to lateral diffusion of bleached and unbleached fl-SAv was monitored through acquisition of post-bleach images over a period of typically 10 min.

The images acquired using this protocol were then analysed by ‘time-resolved profile analysis’, a custom-made algorithm [32] implemented in Matlab (MathWorks, MA, USA). Briefly, each post-bleach fluorescence image was first corrected for background fluorescence, spatial aberrations and intensity fluctuations and then radially averaged. The radial intensity profiles thus obtained were compared with numerical solutions of a diffusion equation, where the first post-bleach image defined the initial conditions for the diffusion process. A lateral diffusion model with one mobile fraction and one immobile fraction was found to reproduce our data well. This model has two independent fitting parameters, namely the size and diffusion constant of the mobile fraction. These were computed through global minimization of the root-mean-square differences between numerical predictions and all post-bleach profiles.

3. Results

We tested the effect of several extracellular signalling molecules on HS model matrices, namely the α and γ isoforms of the chemokine CXCL12, the cytokine IFNγ and the growth factors FGF-2 and FGF-9. These were selected based on their known affinity for HS and distinct structural features (figure 1). All proteins bind HS more strongly, or at least as strongly, as other glycosaminoglycans (GAGs) such as chondroitin sulfate or dermatan sulfate [23, 25, 38–41], suggesting that HS serves as their natural ligand in HS-rich extracellular matrices. CXCL12α forms homodimers through the association of β-sheets upon binding to HS, with the known HS binding site being located at the interface between the two monomers (figure 1a). CXCL12γ is distinct from CXCL12α in that it features flexible C-terminal extensions that are also involved in HS binding, and that it is not known to form β-sheet dimers (figure 1b). IFNγ is constitutively present as a homodimer which features a very extended HS binding surface on the flexible C-termini of the monomers (figure 1c). The FGFs are more compact. FGF-2 has three distinct HS binding sites (figure 1d) that are separated from each other by borders of negatively charged and hydrophobic residues. FGF-9, by contrast, features only one HS binding site (figure 1e). As HS matrix model, we employed films of HS chains grafted with the reducing end to a protein-repellant surface (figure 2a). QCM-D allows monitoring of HS film assembly and protein binding as well as analysis of film thickness and mechanical properties (figure 2). FRAP allows for the lateral mobility of HS chains to be probed (figure 3).
indicated by arrows on top of the graph) were consistent with without symbols; at 6–21 min and 46–61 min, respectively, as 10 CXCL12 monolayers with SAv and HS at saturation (figure 2 reflected in the dissipation shift morphological features of the biomolecular film, typically correlating with -sheets (PDB code: 1QG7, where missing residues were added as described in [17]) with its reported HS-binding amino acids [15,17,33] and the first four amino acids, lacking in the CXCL12α(5–67) mutant, indicated (orange). CXCL12γ (b) was constructed from a CXCL12α monomer and the additional 30 amino acid long N-termini modelled as previously reported [23]. IFN-γ (c; PDB code: 1HIG [34]) is shown as a homodimer with the C-termini (residues 120–143, absent in the structure) built as extended β-strands. FGF-2 (d; PDB code: 1FQ9 [35]) and FGF-9 (e; PDB code: 1H9K [36]) are shown as monomers with their known HS binding sites, i.e. three sites for FGF-2 [37] and a single, extended site for FGF-9 [25].

Figure 1. Structures of soluble extracellular signalling proteins used in this study. Structures are surface plots, all drawn at the same scale (scale bar indicated in (a)). Amino acids known to contribute to primary and secondary HS binding sites are shown in dark and light blue, respectively; the remaining protein surfaces are coloured in grey, or in light brown for the second monomer in the structures of homodimers; the position of selected N or C terminals are marked with an arrow. CXCL12α (a) is shown as a homodimer associated through β-sheets (PDB code: 10G7, where missing residues were added as described in [17]) with its reported HS-binding amino acids [15,17,33] and the first four amino acids, lacking in the CXCL12α(5–67) mutant, indicated (orange). CXCL12γ (b) was constructed from a CXCL12α monomer and the additional 30 amino acid long N-termini modelled as previously reported [23]. IFN-γ (c; PDB code: 1HIG [34]) is shown as a homodimer with the C-termini (residues 120–143, absent in the structure) built as extended β-strands. FGF-2 (d; PDB code: 1FQ9 [35]) and FGF-9 (e; PDB code: 1H9K [36]) are shown as monomers with their known HS binding sites, i.e. three sites for FGF-2 [37] and a single, extended site for FGF-9 [25].

3.1. Design of HS model matrix

Our HS films present HS in an oriented manner and at controlled density (figure 2a) [7]. Gold supports were first coated with a monolayer of OEG exposing terminal biotin groups at controlled surface density. A monolayer of SAv was then formed and used to anchor HS through a biotin moiety that was conjugated to the GAG’s reducing end [7]. Binding in this orientation effectively reproduces the attachment of HS to core proteins in HSPGs [42], and minimizes effects of biotin conjugation and surface-confinement on protein binding. The SAv-on-OEG film inhibits non-specific protein binding to the surface, i.e. measured responses are exclusively because of specific interactions.

QCM-D was used to validate correct assembly of the model surface and to characterize the effect of protein binding on HS films. The QCM-D response is sensitive to the amount of adsorbed ligand (including coupled solvent), with a negative frequency shift $\Delta f$ typically correlating with a mass increase, and to mechanical properties, as well as morphological features of the biomolecular film, typically reflected in the dissipation shift $\Delta D$ [31].

QCM-D responses upon sequential incubation of OEG monolayers with SAv and HS at saturation (figure 2b, curves without symbols; at 6–21 min and 46–61 min, respectively, as indicated by arrows on top of the graph) were consistent with the formation of a relatively rigid SAv-monolayer (i.e. with $\Delta f = -23 \pm 1$ Hz and a low dissipation shift, $\Delta D \leq 0.3 \times 10^{-6}$, at saturation) and a soft, hydrated HS layer (i.e. with $\Delta f = -28.5 \pm 1.0$ Hz and a high dissipation shift, $\Delta D = 5.0 \pm 0.2 \times 10^{-6}$, at saturation), respectively. As reported in our previous study [7], the frequency shift for such an HS film (henceforward called high-density HS film) corresponds to an areal mass density of $35.5 \pm 2.2$ ng cm$^{-2}$, and to a water content of $96.9 \pm 0.5\%$. In this earlier work, we had also estimated the mean distance between adjacent HS anchor sites to be 5 nm, consistent with the dimensions of SAv, and the mean length of the surface-bound HS chains to be 20 monosaccharides (or 10 nm); in this regard, we note that the mean length of surface-bound b-HS chains is shorter than the mean length in the solution from which they were bound, because shorter chains bind preferentially [7]. In essence these numbers indicate that, while there is plenty of space for small proteins to bind into the HS films, the pendant HS chains are long enough to make contact with their neighbours and cover the whole surface area.

3.2. Effect of CXCL12α binding on HS films

Exposure of the chemokine CXCL12α at a concentration of 0.64 μM to the high-density HS film generated a negative frequency shift $(-9 \pm 1$ Hz; figure 2b, blue curve without symbols, 74 to 90 min), confirming CXCL12α binding. The concomitant change in dissipation was pronounced and negative $(-3.8 \pm 0.2 \times 10^{-5}$; figure 2b, red curve without symbols). Such a QCM-D response provides a strong indication that the chemokine rigidifies the HS film. Quantitative analysis of the
QCM-D data through viscoelastic modelling revealed decreases in the elastic compliance $J_0$ and the viscous compliance $J_{00}$ upon CXCL12α binding (figure 2c). $J_0$ and $J_{00}$ are physical parameters (elastic and viscous contributions, respectively) related to film softness, and their decrease thus confirms film rigidification. This analysis also revealed that the protein induces a moderate decrease in film thickness (figure 2c). Upon subsequent rinsing in buffer, frequency and dissipation increased slowly, but did not return to the level of the virgin HS film (figure 2b, curves without symbols; from 89 min), demonstrating that some, but not all CXCL12α is released over experimentally accessible time scales, and that the HS film partially recovers its original morphology.

To test if the protein-induced morphological changes depend on HS surface density, we repeated the QCM-D assay at reduced HS surface coverage (figure 2b, curves with square symbols). To this end, b-HS was incubated either at 50 μg ml$^{-1}$ to saturation (‘high-density HS films’, curves without symbols) or at 1 μg ml$^{-1}$ for 15 min to reach about 30% of maximal coverage (‘low-density HS films’, curves with square symbols). CXCL12α, incubated at 0.64 μM, induced dissipation decreases for both HS densities, indicating rigidification of the hydrated HS film upon chemokine binding. (c) Elastic compliance $J$, viscous compliance $J'$ and thickness of HS films obtained from QCM-D data for high-density HS films, bare and with CXCL12α up to binding equilibrium. Data correspond to mean and standard error of the mean from three independent experiments. All parameters decreased upon CXCL12α incubation, confirming film rigidification and compaction.
3.3. Effect of CXCL12α binding on HS chain mobility

We hypothesized that the rigidification and thinning of HS films is due to cross-linking of HS chains by the chemokine. However, an alternative explanation could be that individual HS chains wrap around CXCL12α molecules, thereby stiffening the film and reducing the film thickness without generating any inter-chain cross-links. To distinguish between these two scenarios, we tested how the chemokine affects the lateral mobility of HS chains.

To this end, we used a modified model surface in which the gold-supported OEG monolayer was replaced by a silica- or glass-supported lipid bilayer (SLB; figure 3a). The oriented immobilization of HS at controlled densities is retained on these surfaces and the SAv-on-SLB film is also effectively passivating against non-specific binding of proteins [7]. SLBs are distinct, however, in that they provide a fluid surface on which SAv, and the SAv-bound b-HS, have the freedom to move laterally (schematically shown in figure 3a).

The lateral mobility was probed by FRAP, using fluorescently labelled SAv (fl-SAv) as b-HS anchors. In this method, a limited surface area is rapidly bleached and diffusion of fluorescent molecules into (and bleached molecules out of) the bleached area is subsequently monitored.
We verified correct surface functionalization by QCM-D (figure 3b). The fraction of biotinylated lipids used to form SLBs was adjusted to 0.5% such that incubation of fl-SAv at saturation (figure 3b, 10 to 20 min) led to a partial protein monolayer, in which the SAv molecules diffused freely, i.e. without being appreciably hindered by two-dimensional crowding. The fluorescent label did not induce any non-specific binding of CXCL12α or HS (figure 3b, 29 to 37 min and 44 to 51 min, respectively). The shifts in frequency (−9 ± 1 Hz) and dissipation (2.0 ± 10−3) for incubation of b-HS at saturation (figure 3b, 58 to 68 min) were comparable with the low-density HS film shown in figure 2b. Moreover, the QCM-D responses upon subsequent binding of CXCL12α (figure 3b, 92 to 105 min) were also similar to those observed in figure 2b. This indicates that the FRAP measurements can be directly correlated with QCM-D measurements on low-density HS films.

The representative fluorescence micrographs in figure 3c demonstrate close-to-complete recovery of virgin b-HS films within 100 s, confirming that fl-SAv with HS is indeed laterally mobile, as desired. By contrast, the bleached spot remained clearly visible after 100 s when CXCL12α was added to the HS film. Radially averaged fluorescence intensity profiles were computed from time-lapse series of micrographs after photobleaching, and analysed to quantify lateral mobility. To this end, the pool of fl-SAv was assumed to be distributed in two distinct fractions, one immobile and the other laterally mobile with a given diffusion constant. The size of the mobile fraction and its diffusion constant are shown in figure 3d.e. These quantitative results confirm that virtually all (i.e. ≥95%) fl-SAv in a virgin SAv-monolayer was mobile, and that the mobility was unaffected by the presence of b-HS. In the presence of CXCL12α, 40% of the fl-SAv became effectively immobilized, and additionally, the diffusion constant of the retained mobile fraction was strongly reduced (by 45%). These data provide evidence that CXCL12α impedes lateral motion of HS and its fl-SAv anchor, and we propose that this immobilization is the consequence of CXCL12α-mediated HS cross-linking.

After treatment with 2 M GuHCl, which we know effectively releases all CXCL12α from HS while keeping the HS film intact [7], the mobile fraction and its diffusion constant largely returned to the values observed for a virgin HS film. This confirms that HS mobility is restored upon chemokine release, i.e. the cross-linking is reversible and requires the presence of the chemokine. The mobile fraction though remained marginally reduced, indicating that a small fraction of fl-SAv remains permanently immobile upon GuHCl treatment. Most probably, the lack of complete regeneration is due to a weak yet irreversible perturbation of the fl-SAv film by GuHCl: detailed inspection of the fluorescent micrographs after GuHCl treatment revealed bright spots that we believe are fl-SAv aggregates.

3.4. Effect of CXCL12α mutations on HS cross-linking

CXCL12α is known to form β-sheet dimers (figure 1a) upon binding to HS [15]. To test if this oligomerization is involved in HS cross-linking, we additionally tested two CXCL12α constructs with point mutations that leave the ternary structure of CXCL12α essentially intact, but alter the ability of the protein to form β-sheet dimers: L366C/A65C mutations result in inter-molecular disulfide bonds and formation of a ‘locked dimer’ [22] while I55C/L58C mutations promote an intra-molecular disulfide bond and formation of a ‘partial monomer’ with a reduced propensity to form dimers [21].

We tested the effect of binding of these constructs to low- and high-density HS films by QCM-D, and HS mobility in low-density HS films by FRAP. As with the wild-type, both mutants bound to HS films (figure 4a, blue curves), but not to the supporting SAv-monolayer (figure 4a, grey curves with triangle symbols). Binding to HS was distinct, however, with regard to the magnitude of the frequency shift at equilibrium and reversibility upon elution in buffer. The locked dimer exhibited enhanced and more stable binding, whereas binding was reduced and less stable for the partial monomer, as compared with native CXCL12α. These systematic variations reflect the importance of CXCL12α dimerization in stabilizing the interaction between the protein and HS [21].

Interestingly, both mutants also generated pronounced decreases in dissipation (figure 4a, red curves) upon binding to HS, albeit with different magnitudes. Parametric plots of the \( \Delta f / \Delta f' \) ratio as a function of \( -\Delta f' \) are shown in figure 4b. At a given HS density, the curves were very similar for all three protein constructs, except at the highest magnitudes of \( \Delta f' \). For thin films, the \( \Delta f / -\Delta f' \) ratio is proportional to the elastic compliance \( j' \) [31] and thus a simple relative measure for softness, whereas \( -\Delta f' \) is a relative measure for the protein surface density. The plots illustrate that the softness of HS films reduces only marginally as the HS grafting density increases during HS film formation (i.e. from \( -\Delta f' = 0 \) to 28.5 ± 1 Hz), and that subsequent protein binding (cf. larger values of \( -\Delta f' \)) reduces the softness drastically and in a coverage-dependent manner. The fact that the \( \Delta f / -\Delta f' \) versus \( -\Delta f' \) curves for protein binding are superimposed indicates that the mechanical properties (and hence the morphologies) of the HS films are comparable for a given HS surface density and protein concentration in the film, irrespective of the quaternary state of the employed protein. This implies that the differences in the magnitude of \( -\Delta f' \) and \( \Delta f' \) at equilibrium are entirely because of differences in the affinity (i.e. the adsorbed amounts), but that the intrinsic propensity of CXCL12α to cross-link HS does not depend on protein oligomerization.

Complementary FRAP assays revealed that the partial monomer and locked dimer can effectively reduce the mobile fraction (figure 4c) and its diffusion constant (figure 4d), confirming that all CXCL12α constructs can indeed cross-link HS. However, an appreciable reduction in mobility for the partial monomer could only be observed after increasing the protein solution concentration (by sixfold). Moreover, after elution of residual partial monomer from the bulk solution with working buffer, the mobile fraction and its diffusion constant returned close to the level of a virgin HS film, whereas both parameters remained unaffected for the locked dimer. This demonstrates that an efficient cross-linking of the HS film requires a minimal protein concentration. Taken together, we conclude that the HS-induced CXCL12α dimerization [21,22] enhances protein binding, but that this dimeric structure is dispensable for HS cross-linking if the reduced affinity is compensated by an increased protein solution concentration. CXCL12α mutants lacking the N-terminal lysine residue have been reported to display reduced affinity for HS based on surface plasmon resonance data [15,33], while nuclear magnetic resonance (NMR) analysis found no direct evidence of interaction with heparin-derived oligosaccharides [19,33]. We hypothesized that this amino acid, which forms the end of a
rather flexible protein domain and is rather distant from all other amino acids known to be involved in HS binding [17], may be important for cross-linking. To test this, we studied an additional construct with a truncated amino acid sequence, i.e. a mutant that lacked the four N-terminal amino acids (CXCL12\(a\)(5–67); figure 1a). The magnitudes of the frequency

\[
\Delta f = -\frac{1}{2} \frac{D}{D_f} \Delta f (10^{-6} \text{Hz}^{-1})
\]

\[
\Delta D = 2 \frac{D}{D_f} \Delta f (10^{-6} \text{Hz}^{-1})
\]

Figure 4. Dimerization and N-terminal lysine are dispensable for HS cross-linking. (a) QCM-D data for the binding of selected CXCL12\(a\) constructs to low-density (curves with square symbols) and high-density (curves without symbols) HS films on SA\(v\) on OEG monolayers. As in figure 2b, \(\Delta f\) and \(\Delta D\) are shown relative to SA\(v\)-coated surfaces before b-HS binding, yet b-HS binding is not explicitly shown. All samples were injected at 0 min and a concentration of 0.64 \(\mu\)M monomer equivalents; arrowheads indicate the start of rinsing in working buffer. Protein binding was also tested on SA\(v\)-monolayers without HS (grey curves with triangle symbols; only shown for \(\Delta f\)) to confirm absence of non-specific binding. Frequency shifts at equilibrium and unbinding curves after rinsing differed between CXCL12\(a\) constructs, indicating that their binding affinities are distinct. However, all constructs induced dissipation decreases on low- and high-density films, indicating HS film rigidification. (b) Parametric plot of \(\Delta D / -\Delta f\) for the protein-loaded HS film (a relative measure for film softness) versus \(-\Delta f\) for protein binding (a relative measure for protein surface density) for the binding data on low-density (left) and high-density (right) HS films displayed in (a) (with colour code as indicated). The curves largely superpose for all four CXCL12\(a\) constructs, indicating that, for a given combination of HS and protein surface densities, the mechanical properties of the HS films are comparable. Representative data for HS film formation (grey) is given for comparison. (c,d) Mobile fractions and their diffusion constants of b-HS (bound to fl-SA\(v\) on SLBs) before incubation with CXCL12\(a\) constructs, after incubation with the proteins at equilibrium (native CXCL12\(a\), CXCL12\(a\)(5–67) and locked dimer at 0.64 \(\mu\)M monomer equivalents, partial monomer at 3.8 \(\mu\)M), and after elution of respective protein from the solution phase, as indicated. The fluorescent label of fl-SA\(v\) was confirmed by QCM-D not to induce any measurable non-specific binding of any of the CXCL12\(a\) constructs (not shown). The mobility data confirm that all CXCL12\(a\) constructs can cross-link HS.

rsob.royalsocietypublishing.org
Open Biol. 5: 150046

Downloaded from http://rsob.royalsocietypublishing.org/ on March 9, 2016
shifts for this construct were comparable with native CXCL12α on high-density HS films and slightly reduced on low-density HS films (figure 4a), consistent with a rather weak contribution of the N-terminal lysine to protein binding. Importantly, the mutant also showed a negative dissipation shift, and the $\Delta D/\Delta f$ versus $-\Delta f$ curves for CXCL12α(5–67) and native CXCL12α at a given HS surface density (figure 4b) were indistinguishable. Moreover, FRAP results (figure 4c,d) confirmed that the mutation does not affect HS mobility. Taken together, these data indicate that the N-terminus is also dispensable for cross-linking, which is presumably consistent with its modest and/or transient interaction with HS [15,17,33].

3.5. Effect of CXCL12α on HS oligomers

Having established that CXCL12α cross-links HS, we next tested if there is a minimal length of HS chains required for cross-linking. CXCL12α binding to HS oligosaccharides of different size was analysed by QCM-D to determine the minimum number of saccharides necessary for CXCL12α binding and cross-linking (figure 5a). No response was observed on hexasaccharides (dp6), while clear binding was present on dp8, dp10 and dp12, confirming that an octasaccharide but not a hexasaccharide is sufficient for efficient binding, in agreement with the literature [15]. The dissipation decreased only slightly yet significantly ($-0.1 \times 10^{-6}$) for dp8, while films of dp10 and dp12 showed pronounced dissipation decreases upon CXCL12α binding. Clearly, the chemokine induced a rigidification of the oligosaccharide HS layers, suggesting that even rather short HS chains can be cross-linked.

Consistent with this interpretation, FRAP measurements on dp12 revealed significant decreases in the mobile fraction and its diffusion constant with CXCL12α (figure 5b,c). No significant effect was observed with dp6, as expected, demonstrating specificity of the assay. The effect of CXCL12α on the mobility of dp12 was, however, rather weak. This indicates that the oligosaccharides assemble into relatively small clusters with largely retained lateral mobility. In other words, longer HS chains are required for a sufficient amount of CXCL12α to bind to each chain and thus to induce effective cross-linking of many HS chains.

3.6. Effect of other HS-binding proteins on HS films

To test whether HS-cross-linking is unique to CXCL12α, we extended our study and systematically investigated the effect of several other HS-binding proteins, namely CXCL12γ, IFNγ, FGFR2 and FGFR9, on high- and low-density HS surfaces by QCM-D, and on low-density HS surfaces by FRAP (figure 6). The structures of all tested proteins are known and HS binding sites have been identified [23,34,36,37,43] (figure 1b–c). As expected, none of the proteins exhibited any significant non-specific binding to the SA-vinyl monolayer (figure 6a, grey curves with triangle symbols).

Compared with CXCL12α (figure 1a), CXCL12γ (figure 1b) features 30 additional amino acids at the C-terminus, which are known to have HS-binding activity and enhance the affinity of CXCL12 for HS: dissociation constants $K_D$ of 200 nM and 1.5 nM have been reported for the α and γ isoforms, respectively [23]. Indeed, CXCL12γ bound more stably and more rapidly than CXCL12α (figures 6a and 4a, respectively, blue curves). The decrease in dissipation for CXCL12γ was pronounced at low and high HS coverage (figure 6a, red curves). The $\Delta D/\Delta f$ versus $-\Delta f$ plots (figure 6b) confirm that this protein also has a strong propensity to rigidify the HS film. In these plots, differences between CXCL12γ and CXCL12α were small, albeit significant compared with the variations between CXCL12α and its mutants (figure 4b), suggesting that there are subtle differences in the morphology of the protein-loaded HS films.
Figure 6. Correlation between structure and HS cross-linking propensity of HS-binding proteins. (a) QCM-D data for binding of proteins to HS films are displayed analogous to figure 4a. CXCL12γ as CXCL12α, induced strong negative shifts in dissipation irrespective of HS film density; FGF-2, but not FGF-9, induced negative dissipation shifts irrespective of HS film density; for IFNγ, the dissipation decreased only on high-density HS films, indicating distinct, protein-specific degrees of HS film rigidification. (b) Parametric plot of $\Delta D/D_f$ for the protein-loaded HS film versus $-\Delta f$ for protein binding for the binding data on low-density (top) and high-density (bottom) HS films displayed in (a); the curves show that HS film rigidification depends on HS surface density, and protein type and coverage. (c,d) Mobile fractions and their diffusion constants of b-HS (bound to fl-SAv on SLBs at low surface density) either bare or in the presence of CXCL12γ, FGF-2 or FGF-9, as indicated. (e,f) Mobile fractions and their diffusion constants of b-HS (bound to fl-SAv on SLBs at low surface density (left graphs) and high surface density (right graphs)) either bare or in the presence of IFNγ, as indicated. The fluorescent label of fl-SAv was confirmed by QCM-D not to induce any measurable non-specific binding of any of the HS-binding proteins (not shown). Protein concentrations used throughout were 0.43 μM for CXCL12γ, 0.29 μM for IFNγ, 0.28 μM for FGF-2 and 0.17 μM for FGF-9. The mobility and rigidification data correlate, confirming that FGF-2 is a potent cross-linker whereas FGF-9 does not cross-link, that CXCL12γ cross-links HS film similarly to CXCL12α locked dimer, and that IFNγ is a rather poor cross-linker.
Nevertheless, CXCL12γ reduced the HS mobile fraction and its diffusion constant (figure 6c,d) somewhat more strongly than native CXCL12α, i.e. to a similar extent as the locked dimer of CXCL12α (figure 4c,d). We conclude that CXCL12γ is also a potent HS cross-linker and that this potency is enhanced by the HS binding stability.

IFNγ is a homodimeric cytokine known to strongly interact with HS (κ0 = 1 nM [39]). The known HS binding site is located at the C terminus and the two C termini in the homodimer are spatially separated (figure 1c). At present, it is not clear, if the two binding loci bind to a single or to two distinct HS chains. IFNγ readily bound to the HS films and binding was very stable as shown by the QCM-D frequency response (figure 6a). In high-density HS films, IFNγ induced a negative shift in dissipation (figure 6a) albeit with a reduced magnitude compared with CXCL12α (figure 4h). However, IFNγ generated a slight increase in dissipation in low-density HS films. FRAP (figure 6e,f, left plots) revealed that IFNγ induces only moderate reductions in the mobile fraction of HS (by 15%) and in the diffusion coefficient of this mobile fraction (by 25%). The lack of dissipation decrease and the weak reduction in HS mobility thus correlate, and indicate that IFNγ does not cross-link HS strongly, at least at low surface density. Under these conditions, the two HS binding sites on the IFNγ homodimer apparently bind within a single HS chain (intra-HS-chain bond).

To test if the decrease in dissipation at high HS surface density (figure 4a) is an indicator for the formation of inter-HS-chain bonds by IFNγ when HS chains are densely packed, we performed additional FRAP measurements at high HS surface densities (figure 6e,f, right plots). To this end, the fraction of biotinylated lipids used to form the SLB was increased (from 0.5 to 5%) to enable formation of a dense fl-SAv-monolayer. Under these conditions, the lateral mobility of the bare HS films was largely retained (i.e. the mobile fraction was only slightly reduced, to 90%) although crowding of fl-SAv entailed a marked reduction of the diffusion constant (from 2 μm² s⁻¹ to 0.5 μm² s⁻¹). Interestingly, the mobile fraction as well as its diffusion constant decreased only weakly in the presence of IFNγ (by 12% and 20%, respectively). This indicates that the IFNγ homodimer prefers to form intra-HS rather than inter-HS-chain bonds even at high HS concentrations, and supports the previously proposed model in which IFNγ binds to two adjacent N-sulfated domains along a single HS chain [44].

FGF-2 and FGF-9 were selected because of their well-characterized HS binding sites (figure 1d,e). FGF-2 has three HS binding sites, of which two are located on the same face and the third on the opposite face of the protein [37,43,45,46]. By contrast, only one (rather extended) HS binding site has been identified for FGF-9 [25]. FGF-2 and FGF-9 were reported to have affinities of 10 and 620 nM, respectively, to heparin dp8 (i.e. a representative of high-affinity binding sites on HS) [25,47]. Both FGFs bound readily to HS films (figure 6a), as expected. The frequency shifts on high-density HS films exceeded those observed for the previously investigated chemokines (figures 4 and 6), indicating extensive binding, FGF-2 generated pronounced decreases in dissipation for high-density and low-density HS films. By stark contrast, the dissipation remained largely unchanged and increased drastically, respectively, for FGF-9. This contrast is also apparent in the ΔD/−Δf versus −Δf plots (figure 6b), where the curves for FGF-9 are located above the curves for FGF-2 irrespective of the HS surface density, thus indicating that FGF-2 is more potent in rigidifying HS films. FRAP revealed a drastic reduction (by 80%) in the mobile fraction with FGF-2 (figure 6c), i.e. this protein essentially immobilized HS. FGF-9, on the other hand, did not affect the mobile fraction at all (figure 6c) and the diffusion constant of the mobile fraction was only weakly affected (figure 6d).

Clearly, FGF-2, but not FGF-9, has a strong propensity to cross-link and to rigidify HS films. In the light of the distinct structural features of these two growth factors, we propose that FGF-2 cross-links HS by accommodating at least two different chains simultaneously in its multiple HS binding sites, whereas only one HS chain at a time can bind to the extended binding site on FGF-9. The results with FGFs highlight that not all HS-binding proteins cross-link HS and that the cross-linking propensity can vary distinctly among proteins of the same family.

4. Discussion

4.1. What are the molecular mechanisms behind HS cross-linking?

One may argue that a protein with an HS-binding surface large enough to accommodate more than one HS chain should be able to cross-link HS. Yet, we found the extension of the HS-binding surface alone to be a poor predictor of a protein’s cross-linking propensity. This is illustrated by the limited cross-linking propensity of the IFNγ homodimer (figure 6), and also by the negligible effects of the elongated C-terminal of CXCL12γ, compared with CXCL12α, on HS film rigidification and cross-linking (figures 4 and 6). Apparently, the formation of multiple bonds with the same HS chain is more favourable in these cases than the inter-connection of several distinct HS chains.

FGF-2, by contrast, exhibited strong cross-linking activity (figure 6). A detailed inspection of the protein’s surface reveals that the three HS-binding patches containing basic amino acids are separated from each other by acidic and hydrophobic amino acids. Such HS-repelling rims are not present in any of the other proteins tested. From the correlation with our experimental data, we thus propose multiple HS-binding patches separated by HS-repelling borders as a distinct structural feature conducive to HS cross-linking.

Mutation of the primary binding site reduces binding of FGF-2 to HS substantially [48], i.e. the affinities of the secondary HS binding sites on FGF-2 are rather weak. Yet, FGF-2 apparently is a potent HS cross-linker. This effect is not surprising if one takes into consideration that, once FGF is sequestered into the matrix through its primary high-afﬁnity binding site, the local concentration in HS is high such that even weak interactions can occur frequently. Thus, the example of FGF-2 illustrates how rather weak secondary binding sites can fulﬁl functions.

CXCL12 is also a potent HS cross-linker (figures 4–6), yet the molecular mechanism of cross-linking must be different since this protein does not feature several clearly separated binding sites. It is instructive to consider the quaternary structure of this protein. Upon HS binding, CXCL12 readily forms homodimers through the association of β-sheets [15], but our tests with partial monomer and locked dimer (figure 4) demonstrated that this ‘β-sheet’ dimer is not directly involved in HS
cross-linking. Crystallographic studies [49] though revealed that CXCL12α can form another homodimer through the association of two N-termini, analogous to what is commonly observed for chemokines of the CC family [50], although the functional significance of the ‘N-terminal’ dimer has so far remained unclear.

We propose that β-sheet and N-terminal dimers coexist in the HS matrix, potentially forming dimers of dimers. In this scenario, the two dimerization mechanisms would have distinct functions, i.e. dimerization through β-sheets enhances the affinity of the protein for HS whereas dimerization through N-termini induces HS cross-linking. Our experimental data are fully consistent with such a scenario. In particular, arginines at positions 8 and 12 were found to be involved in the formation of the N-terminal dimer [49]. These are present in all mutants (including the truncated CXCL12α(5–67) form), and it is thus not surprising that all our CXCL12α constructs exhibited a similar propensity to rigidify and cross-link HS films once the differences in affinity were adjusted for (figure 4b–d). Moreover, an N-terminal dimer can also readily cross-link short HS oligosaccharides (figure 5), whereas such an effect would be difficult to explain with β-sheet dimers alone: in the current binding model, dp8 is just long enough to fit the HS-binding interface in the β-sheet dimer [19]; it would be conceivable that a single dp8 binds two β-sheet dimers (i.e. one on each face of the oligosaccharide), but not the opposite. Future studies with other CXCL12α mutants should be useful to test if the arginines at positions 8 and 12 are indeed crucial for dimerization-mediated cross-linking and how HS binding [19,33] and CXCL12α oligomerization interplay to promote cross-linking. In this regard, it is notable that many chemokines form oligomers, when free in solution or upon binding to GAGs [51]. It will thus also be interesting to investigate how the oligomerization of other chemokines correlates with their propensity for cross-linking GAGs.

4.2. The methodological approach presented in this study is novel

HS films as model matrices present HS at controlled orientation and lateral mobility and at tuneable surface density, thus enabling supramolecular interaction studies under well-defined conditions. The two characterization techniques, QCM-D and FRAP, provide complementary information and together enable identification of the protein’s binding and cross-linking activity. Specifically, QCM-D provides information about binding kinetics, and about HS/protein film morphology (thickness) and rigidity, whereas FRAP enables quantification of the lateral mobility of HS chains. The assay does not require any labelling of the protein and is thus broadly applicable to assess the propensity of proteins to cross-link HS and other GAGs. In particular, some extracellular signalling proteins are known to bind several types of GAGs (e.g. CXCL12γ [23,38] or IFNγ [38–40]) and it will thus be interesting to probe if the propensity of a given protein to cross-link is specific to a particular GAG type.

GAG-on-chip devices are increasingly used to probe the interaction of GAGs with proteins. On such devices, the extent of protein-mediated GAG cross-linking will depend sensitively on the presentation and surface density of GAGs. As a consequence, the binding behaviour of proteins may also vary strongly, calling for care in the interpretation of the read out and comparison of data between different GAG-on-chip-based assays. The method developed here should be very useful to evaluate how GAG presentation and surface density affect binding.

4.3. What is the functional relevance of HS cross-linking by extracellular signalling proteins?

Cross-linking of HS requires the spatial proximity of HS chains. This criterion was met on average in our well-defined model matrices within the range of HS surface densities employed. Based on the typical length of HS chains and the typical density of HS-bearing proteoglycans (PGs), Yanagishita & Hascall [14] estimated that the ensemble of HS chains on cells can readily explore the entire cell surface. This implies that neighbouring HS chains can meet, and HS cross-linking thus may also be a frequent phenomenon at the cell surface and in extracellular matrix. The distribution of HS, however, may not be homogeneous across the cell surface [52] and may vary across cell types and states. This implies that the local HS density can vary over a large range, and that cross-linking may be confined to specific locations. It is thus possible that HS cross-linking is spatio-temporally controlled through the expression of HS and the sequestration of chemokines or growth factors in the course of specific biological processes (e.g. angiogenesis [53], inflammation [54], cell proliferation [6,47,55]). This may have consequences at different levels.

On the level of the matrix, the proteins can promote changes in structure that parallel their signalling activity. The ensuing changes in physical properties of peri- and extracellular matrices, such as permeability, rigidity or thickness, may elicit a range of additional cellular responses. For example, a reduction in the thickness of pericellular coats may facilitate intercellular contacts through membrane-bound cell adhesion receptors/ligands [56], or the cross-linking of HS displayed by two distinct pericellular coats could be important in the initial stage of cell–cell adhesion. Moreover, changes in the rigidity of the cellular glycocalyx through HS cross-linking may provide a physical cue that guides the behaviour of cells.

On the local scale, cross-linking of HS could promote clustering of cell-surface PGs to which the HS chains are attached, thereby activating signalling. Clustering of the HSPG syndecan-4, for example, is important for the binding to and activation of protein kinases which ultimately determine the assembly of focal adhesions and the organization of the actin cytoskeleton [57]. In this regard, it has been demonstrated that a syndecan-4 dimer requires a minimum of four HS chains to be functional, whereas a mutated form of syndecan-4 with a single HS chain was not functional unless a cluster of multiple syndecan-4 dimers was formed. This suggests that multiple HS chains must associate in the presence of a ligand, to form a signalling unit [58]. In this scenario, HS-cross-linking proteins would elicit signalling activity in a way that has thus far not been appreciated. Moreover, the interaction between FGFs and syndecans has been demonstrated to promote their clustering, activation of protein kinase Ca, translocation to cholesterol-rich membrane domains and eventually internalization and transfer of FGF-2 to the nucleus [59–62]. Thus, ligands that do not cause cross-linking of HS chains, such as IFNγ and FGF-9, may not be able to activate these parallel, HS-specific signalling pathways. A further
HS-dependent pathway that may be activated by ligands that cross-link HS chains on syndecans is the formation of exosomes [63]. Future studies comparing the effect of proteins that cross-link HS (e.g. FGF-2, CXCL12α or CXCL12γ) with those that do not (e.g. IFNγ or FGF-9) would provide a direct test if HS cross-linking is important for exosome formation and other HS-specific signalling pathways. Last but not least, the proteins themselves would also be affected by HS cross-linking, in that the attachment through multiple binding sites reduces their mobility. This may contribute, for example, to the substantial fraction of FGF-2 that is observed to undergo confined, rather than diffusive motion in pericellular matrix [52].

5. Conclusion

In summary, we have demonstrated that extracellular signalling proteins can cross-link GAGs and propose that several binding sites, well separated either through GAG-repellent borders on the protein’s surface (e.g. FGF-2) or through spatial separation in quaternary protein structures (e.g. N-terminal CXCL12 dimers), are required for GAG cross-linking. This prediction can now readily be tested with other GAG-cross-linking proteins using the here-presented GAG cross-linking assay. The ability of extracellular signalling proteins to influence matrix organization and physico-chemical properties implies that the functions of these proteins may not simply be confined to the activation of cognate cellular receptors. This may have far-reaching implications for cell–cell and cell–matrix communication, and our predictions can be tested in future cell and in vivo assays.

Authors’ contributions. E.M. and D.T. carried out surface preparation, QCM-D and FRAP measurements; D.T., R.S., D.P.D., Y.L., C.S. and B.F.V. prepared heparan sulfate conjugates and proteins; J.K. performed data analysis methods; E.M., D.P.D., T.M.H., L.C.-G., D.G.F. and H.L.-J. helped design the study and draft the manuscript; L.C.-G. helped coordinate the study; E.M. and R.P.R. wrote the manuscript; R.P.R. conceived of and coordinated the study. All authors gave final approval for publication.

Competing interests. We declare we have no competing interests.

Funding. We acknowledge funding by the Nanoscience Foundation Chair of Excellence Project ‘GAG2D’ and the European Research Council Starting Grant ‘JELLY’ (FP7-ERC-2012-StG-306433) to R.P.R., the National Institutes of Health (NIH, USA) grant no. R01 AI37113 to T.M.H., the North West Cancer Research (UK) and the Cancer and Polio Research Fund (UK) to D.T., NIH grant R01 AR58072 to B.F.V., the Nanobio programme and the French National Research Agency via Labex ARCANE (ANR-11-LABX-0003-01).

Acknowledgements. We thank Severin Ehet (CIC biomaGUNE, San Sebastian, Spain) for the preparation of small unilamellar vesicles and support for FRAP measurements and data analysis; Catherine Picart and Fabian Dalonneau (LMGP, Grenoble, France) for access to and support for the confocal microscope, respectively; Damien Maurin (IBS, Grenoble, France) for the purification of IFNγ and CXCL12γ and Françoise Baleux (Institut Pasteur, Paris, France) for providing the CXCL12α(5–67) mutant.

References

1. Rapraeger AC, Knudka A, Olwin BB. 1991 Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252, 1705–1708. (doi:10.1126/science.1646484)
2. Aviezer D, Yayon A. 1994 Heparin-dependent binding and autoprophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc. Natl Acad. Sci. USA 91, 12 173 – 12 177. (doi:10.1073/pnas.91.25.12173)
3. Zischon TF et al. 1995 Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J. Biol. Chem. 270, 16 871 – 16 878. (doi:10.1074/jbc.270.28.16871)
4. Amara A et al. 1999 Stomatal cell-derived factor-1alpha associates with heparan sulfates through the first β-stand of the chemokine. J. Biol. Chem. 274, 23 916 – 23 925. (doi:10.1074/jbc.274.34.23916)
5. BrOMUXeyer HE, Cooper S, Hangac G, Kim CH. 2005 Stomatal cell-derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro. Stem Cells Dev. 14, 199–203. (doi:10.1089/scd.2005.14.199)
6. Turbic A, Leong SY, Turnley AM. 2011 Chemokines and inflammatory mediators interact to regulate adult murine neural precursor cell proliferation, survival and differentiation. PLoS ONE 6, e25406. (doi:10.1371/journal.pone.0025406)
7. Migliorini E, Thakar D, Sadir R, Pleiner T, Baleux F, Lortat-Jacob H, Coche-Guerrante L, Richter RP. 2014 Well-defined biomimetic surfaces to characterize glycosaminoglycan-mediated interactions on the molecular, supramolecular and cellular levels. Biomaterials 35, 8903–8915. (doi:10.1016/j.biomaterials.2014.07.017)
8. Biss MD, Humphries MJ. 2002 Cytoplasmic interactions of syndecan-4 orchestra adherence receptor and growth factor receptor signalling. Biochem. J. 368, 1–15. (doi:10.1042/BJ20021228)
9. Li J-P, Vlodavsky I. 2009 Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 102, 823–828.
10. Blackhall FH, Merry CL, Davies EJ, Jayson GC. 2001 Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85, 1094–1098. (doi:10.1054/bj.2001.2054)
11. Vanhaverbeke C, Simone-P J-P, Sadir R, Gans P, Lortat-Jacob H. 2004 NMR characterization of the interaction between the C-terminal domain of interferon-γ and heparin-derived oligosaccharides. Biochem. J. 384, 93–99. (doi:10.1042/BJ20040757)
12. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. 2000 Crystal structures of two FGF–FGFR complexes reveal the determinants of ligand–receptor specificity. Cell 101, 413–424. (doi:10.1016/S0092-8674(00)08581-X)
13. Weber M, Haushild R, Schwarz J, Mousson C, De Vries I, Legler DF, Luther SA, Bollenbach T, Sixt M. 2013 Intracellular dendritic cell guidance by haptotactic chemokine gradients. Science 339, 328–332. (doi:10.1126/science.1228456)
14. Yanagishita M, Hascell VC. 1992 Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 267, 9451–9454.
15. Sadir R, Baleux F, Grousdidier A, Imberty A, Lortat-Jacob H. 2001 Characterization of the stromal cell-derived factor-1α-heparin complex. J. Biol. Chem. 276, 8288–8296. (doi:10.1074/jbc.M008110200)
16. Mullow B, Gee C, Wheeler SF, Wait R, Gray E, Barowciville TW. 1997 Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb. Haemost. 77, 668–674.
17. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. 2004 Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 279, 43 854–43 860. (doi:10.1074/jbc.M040539200)
18. Thakar D, Migliorini E, Coche-Guerrante L, Sadir R, Lortat-Jacob H, Boturyn D, Renaudet O, Labbe P, Richter RP. 2014 A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans. Chem. Commun. 50, 15 148–15 151. (doi:10.1039/C4CC06905F)
19. Laguri C, Sapay N, Simone-P J-P, Brutscher B, Imberty A, Gans P, Lortat-Jacob H. 2011 13C-labeled heparan sulfate analogue as a tool to study protein/heparan sulfate interactions by NMR spectroscopy.
application to the CXCL12ex chemokine. J. Am. Chem. Soc. 133, 9642–9645. (doi:10.1021/ja201753e)

20. Denoyer A et al. 2012 CXCR3 antagonism of SDF-1 (5–67) restores trabecular function and prevents retinal neurodegeneration in a rat model of ocular hypertension. PLoS ONE 7, e37873. (doi:10.1371/journal.pone.0037873)

21. Ziaiek JI, Gettschew AE, Butler SJ, Taleyaki, Stephens B, Kufareva I, Handel TM, Payne RJ, Volkman BF. 2013 Sulfopetide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allosterically. ACS Chem. Biol. 8, 1955–1963. (doi:10.1021/cb400274a)

22. Veldkamp CT, Seibert C, Peterson FC, Denoyer A et al. 2012. Hearing what you cannot see and visualizing what you hear: interpreting quartz crystal microbalance data from solvated interfaces. Anal. Chem. 83, 8838–8848. (doi:10.1021/ac201778h)

23. Kühne J. 2007 Lipid assemblies on nanostructured surfaces. Diploma thesis, Faculty of Physics and Astronomy, University of Heidelberg.

24. Ziaiek JI et al. 2013 Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus. J. Biol. Chem. 288, 737–746. (doi:10.1074/jbc.M112.394064)

25. Xu R. 2009. The novel CXCL12 gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCL12. PLoS ONE 2, e1110. (doi:10.1371/journal.pone.0001110)

26. Laguri C, Sadir R, Rueda P, Baleux F, Gans P, Arenzana-Seisdedos F, Lortat-Jacob H. 2007 The lethal domain of interferon-gamma. Science 258, 1069–1073. (doi:10.1126/science.1156705)

27. Laguri C, Sadir R, Maurin D, Thomas A, Imbery A, Lortat-Jacob H. 2007 Insights into the mechanism by which interferon-gamma stabilizes a basic amino acid cluster. J. Am. Chem. Soc. 129, 9384–9390. (doi:10.1021/ja072688v)

28. Xu R et al. 2012 Diversification of the structural determinants of fibroblast growth factor–heparin interactions: implications for binding specificity. J. Biol. Chem. 287, 40 061–40 073. (doi:10.1074/jbc.M111.398826)

29. Richter R, Mukhopadhyay A, Brisson A. 2003 Pathways of lipid vesicle deposition on solid surfaces: a combined QCM-D and AFM study. Biophys. J. 85, 3035–3047. (doi:10.1016/S0006-3495(03)74722-5)

30. Altgäde N, Niliakos E, De Battise L, Pashkuleva I, Reis RL, Becher J, Möllner S, Schnabelrauch M, Svedhem S. 2013 Probing the biofunctionality of biotinylated hyaluronan and chondroitin sulfate by hyaluronidase degradation and aggrecan interaction. Acta Biomater. 9, 8158–8166. (doi:10.1016/j.actbio.2013.05.031)

31. Osman ND, Kwon WC, Skett SE, Coombes DR. 2002 Protein–heparin interactions measured by BIACore 2000 are affected by the method of heparin immobilization. Anal. Biochem. 310, 199–207. (doi:10.1016/S0003-1569(02)00396-2)

32. Domack A, Prucker G, Ruhe J, Johannsson D. 1997 Swelling of a polymer brush probed with a quartz crystal resonator. Phys. Rev. E 56, 680–689. (doi:10.1103/PhysRevE.56.680)

33. Eisele NB, Anderson FL, Frey S, Richter RP. 2012 Viscoelasticity of thin biomolecular films: a case study on nucleoporin phenylalanine-glycine repeats grafted to a histidine-tag capturing QCM-D sensor. Biomembranes 13, 2322–2332. (doi:10.1021/bm3005575)

34. Revilakie I, Johannsmann D, Richter RP. 2011 Hearing what you cannot see and visualizing what you hear: interpreting quartz crystal microbalance data from solvated interfaces. Anal. Chem. 83, 8838–8848. (doi:10.1021/ac201778h)

35. Eisele NB, Andersson FI, Frey S, Richter RP. 2012 Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 3, a004952. (doi:10.1101/cshperspect.a004952)

36. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. 1995 Heparin structure and interactions with basic fibroblast growth factor. Science 271, 1116–1120. (doi:10.1126/science.271.5252.1116)

37. Lortat-Jacob H, Turnbull JE, Grimaud JA. 1995 Molecular organization of the interferon-gamma-binding domain in heparan sulfate. Biochem. J. 310, 497–505.

38. KimseIa L, Chen HL, Smith JA, Rudland PS, Fergus DG. 1998 Interactions of putative heparin-binding domains of basic fibroblast growth factor and its receptor, FGF-1, with heparin using synthetic peptides. Glycobiol. J. 15, 419–422. (doi:10.1023/A:1009861048655)

39. Baird A, Schubert D, Ling N, Guillenrin R. 1988 Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc. Natl Acad. Sci. USA 85, 2324–2328. (doi:10.1073/pnas.85.7.2324)

40. Delehedde M, Lyon M, Gallagher JT, Rudland PS, Fergus DG. 2002 Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochem. J. 366, 235–244.

41. Thompson LD, Pantoliano MW, Springer BA. 1994 Energetic characterization of the basic fibroblast growth factor–heparin interaction: identification of the heparin binding domain. Biochemistry 33, 3831–3840. (doi:10.1021/bi00179a006)

42. Murphy IW, Yuan H, Kong Y, Xiong Y, Lollo EJ. 2009 Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family. Proteins 78, 1331–1337. (doi:10.1002/prot.22666)

43. Lortat-Jacob H, Grimaud JA, Imbery A. 2002 Structural diversity of heparan sulfate binding domains in chemokines. Proc. Natl Acad. Sci. USA 99, 1229–1234. (doi:10.1073/pnas.032497699)

44. Salanga C, Handel TM. 2011 Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317, 590–601. (doi:10.1016/j.yexcr.2011.01.004)

45. Duchesne L, Outeau V, Bearon RN, Beckett A, Prior IA, Lounis B, Fergus DG. 2012 Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol. 10, e1001361. (doi:10.1371/journal.pbio.1001361)

46. Cao R, Brökenholt E, Pavlus I, Riwanto D, Post MJ, Wahlberg E, Leboulch P, Cao Y. 2003 Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 504–513. (doi:10.1038/nm848)

47. Poznansky MC, Olszak IT, Fowxall R, Evans RH, Luster AD, Scadden DT. 2000 Active movement of T cells away from a chemokine. Nat. Med. 6, 543–548. (doi:10.1038/75022)

Downloaded from http://rsob.royalsocietypublishing.org/ on March 9, 2016
55. Sahni A, Sporn LA, Francis CW. 1999 Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. *J. Biol. Chem.* 274, 14936 – 14941. (doi:10.1074/jbc.274.21.14936)

56. Weinbaum S, Tarbell JM, Damiano ER. 2007 The structure and function of the endothelial glycocalyx layer. *Annu. Rev. Biomed. Eng.* 9, 121 – 167. (doi:10.1146/annurev.bioeng.9.060906.151959)

57. Couchman JR. 2003 Syndecans: proteoglycan regulators of cell-surface microdomains? *Nat. Rev. Mol. Cell Biol.* 4, 926 – 937. (doi:10.1038/nrm1257)

58. Gopal S, Bober A, Whiteford JR, Multhaupt HAB, Yoneda A, Couchman JR. 2010 Heparan sulfate chain valency controls syndecan-4 function in cell adhesion. *J. Biol. Chem.* 285, 14247 – 14258. (doi:10.1074/jbc.M109.056945)

59. Chu CL, Buczek-Thomas JA, Nugent MA. 2004 Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. *Biochem. J.* 379, 331 – 341. (doi:10.1042/BJ20031082)

60. Hsia E, Richardson TP, Nugent MA. 2003 Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. *J. Cell. Biochem.* 88, 1214 – 1225. (doi:10.1002/jcb.10470)

61. Tkachenko E, Lutgens E, Stan R-V, Simons M. 2004 Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. *J. Cell. Sci.* 117, 3189 – 3199. (doi:10.1242/jcs.01190)

62. Tkachenko E, Simons M. 2002 Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. *J. Biol. Chem.* 277, 19946 – 19951. (doi:10.1074/jbc.M200841200)

63. Baietti MF et al. 2012 Syndecan – syntenin – ALIX regulates the biogenesis of exosomes. *Nat. Cell Biol.* 14, 677 – 685. (doi:10.1038/ncl.2502)